Navigation Links
Treatment approach to human Usher syndrome: Small molecules ignore stop signals
Date:7/1/2011

This release is available in German.

Usher syndrome is the most common form of combined congenital deaf-blindness in humans and affects 1 in 6,000 of the population. It is a recessive inherited disease that is both clinically and genetically heterogeneous. In the most severe cases, patients are born deaf and begin to suffer from a degeneration of the retina in puberty, ultimately resulting in complete blindness. These patients experience major problems in their day-to-day life. While hearing loss can be compensated for with hearing aids and cochlea implants, it has not proven possible to develop a treatment for the associated sight loss to date. Researchers at Johannes Gutenberg University Mainz (JGU) in Germany have now developed a new treatment approach to this disease.

In previously conducted research into this subject, the research team headed by Professor Uwe Wolfrum of the Institute of Zoology at Mainz University had already gained insight into of the fundamental molecular processes and mechanisms causing this debilitating syndrome. Using the results of this successful basic research, the Usher treatment team in Mainz headed by Dr Kerstin Nagel-Wolfrum has now evaluated potential ocular treatment options. Their attention was focused on a mutation identified in a specific German family known to develop the most severe form of Usher syndrome. This mutation is a so-called nonsense mutation in the USH1C gene, which leads to the generation of a stop signal in a DNA base, resulting in premature termination of protein synthesis.

The Mainz research team has now published its latest work on pharmacogenetic strategies for the treatment of Usher syndrome patients with nonsense mutations in the May edition of the journal Human Gene Therapy. The researchers were able to show that a small molecule known as PTC124 (Ataluren) causes the stop
'/>"/>

Contact: Dr. Kerstin Nagel-Wolfrum
nagelwol@uni-mainz.de
49-613-139-20131
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IOF calls for improved strategies to close the treatment gap and reduce future burden of fractures
2. Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
3. Potential treatment for deadly E. coli disease
4. Research reveals effectiveness of seizure treatments for children with autism
5. Therapies to improve biochemical functions hold promise as treatments for autism
6. Cancer drug holds promise as first treatment for common, inherited dementia
7. Arthritis patients taking newer treatments do not have an overall increased cancer risk
8. Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack
9. Several abstracts on gout reveal true burden of disease and highlight promising new treatments
10. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
11. Recycling of Alzheimers proteins could be key to new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... researchers have found one more reason to exercise: working out ... improving overall health by boosting the body,s capacity to make ... to become fat or bone, depending on which path they ... Department of Kinesiology,s Gianni Parise has shown that aerobic exercise ...
... Wildlife Conservation Society applauds the government of Santa Fe Province ... used in hunting of waterfowl, the first such action of ... hunting season, the regulation requires hunters to reduce usage of ... that may lead to the eventual ban of lead shot. ...
... first report of the presence of alternative lengthening of ... endometrium, esophagus, gallbladder, liver, and lung was published today ... presence of ALT in carcinomas can be used as ... of anti-cancer drug therapies. Telomeres are nucleoprotein ...
Cached Biology News:Exercise boosts health by influencing stem cells to become bone, not fat, McMaster researchers find 2Argentina's Santa Fe government reducing lead ammunition for sports hunters 2Researchers report new understanding of role of telomeres in tumor growth 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... revenues increase 22% for fiscal 2009; on track for ... 16 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (MBX:TSX) a biotechnology ... financial results for fourth quarter and full-year 2009. For ... revenues of $6.08 million, a 22% increase from the ...
... , , Trial conducted pursuant to ... , QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris ... a global biopharmaceutical company focused on oncology and endocrine ... Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 ...
... , , HAMBURG, Germany, December ... Verigene(R) and Verigene(R) SP systems for,infringement of European patent EP ... quantification of a target compound". The import,ban covers any and ... European Union. Customs authorities are required to confiscate any,violating products. ...
Cached Biology Technology:Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2
... The versatile ST-195 allows real-time observations of ... This instrument has 64 different strain parameters ... incubator. The thin silicon strain chamber used ... microscopes and fluorescence microscopy. ST-195 can be ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
... reagents package is used for determining protein concentration ... The RC DC protein assay is a colorimetric ... standard assays: 250 ml RC reagent I, 250 ... tartrate solution, 2 L dilute Folin reagent, and ...
... used in conjunction with the EasyCount System to ... The ViaSure Staining Reagent uses a mixture of ... Ethidium Bromide to identify live and dead cells, ... Slide 6 Multi-well Slide provides the ability ...
Biology Products: